Welcome to our dedicated page for Orgenesis SEC filings (Ticker: ORGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orgenesis Inc. filings document the regulatory record of a Nevada biotechnology company focused on cell and gene therapies and decentralized cell processing. Its 8-K disclosures report material definitive agreements, financing arrangements, shareholder voting matters, governance items, and capital-structure changes involving common stock, convertible loans, credit facilities, and warrants.
The filings also document ORGS security status following Nasdaq delisting procedures, Form 25 removal from exchange registration, continued Exchange Act registration under Section 12(g), and OTC market tier changes. These records provide formal disclosure of the company’s public-company status, registered common stock, material events, and governance framework.
Orgenesis Inc. reported issuing an Alpha Warrant to Alpha Prosperity Fund SPC in connection with a previously agreed convertible loan and credit facility. The warrant relates to the first $1,000,000 drawdown under a $1,000,000 convertible loan and $10,000,000 credit facility and is exercisable for 3,289,490 shares of common stock for an aggregate exercise price of $250,000 over three years. The company states that the Alpha Warrant and the shares issuable upon exercise were issued without registration under the Securities Act, relying on the Section 4(a)(2) exemption for transactions not involving a public offering.
Orgenesis Inc. entered into a Convertible Loan Agreement through its subsidiary Theracell Laboratories IKE with Alpha Prosperity Fund SPC. The lender is providing an initial $1,000,000 loan at a simple interest rate of 10% per year, maturing in 36 months. Theracell may fully prepay during the first 30 days; afterward any repayment needs lender approval.
After 30 days and until maturity, the lender can choose to convert the outstanding amount into equity of either Orgenesis or Theracell so that it would hold up to 80% of the applicable company’s outstanding share capital, with any conversion into Orgenesis shares requiring shareholder approval. The agreement also grants a warrant to buy 15% of fully diluted share capital of Orgenesis or Theracell for a total exercise price of $250,000, plus additional similar warrants with each extra $1,000,000 draw. The facility provides up to $10,000,000, under which $7,083,857 has been drawn and $6,083,857 of prior debt was repaid. After 30 days and required approvals, the lender may appoint three directors to Orgenesis’ board.
Orgenesis Inc. entered into a Convertible Loan Agreement through its subsidiary Theracell Laboratories IKE with Alpha Prosperity Fund SPC. The lender is providing an initial $1,000,000 loan at a simple interest rate of 10% per year, maturing in 36 months. Theracell may fully prepay during the first 30 days; afterward any repayment needs lender approval.
After 30 days and until maturity, the lender can choose to convert the outstanding amount into equity of either Orgenesis or Theracell so that it would hold up to 80% of the applicable company’s outstanding share capital, with any conversion into Orgenesis shares requiring shareholder approval. The agreement also grants a warrant to buy 15% of fully diluted share capital of Orgenesis or Theracell for a total exercise price of $250,000, plus additional similar warrants with each extra $1,000,000 draw. The facility provides up to $10,000,000, under which $7,083,857 has been drawn and $6,083,857 of prior debt was repaid. After 30 days and required approvals, the lender may appoint three directors to Orgenesis’ board.